Free tool
FAERS Monitor: Aldactazide
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 012616 or its brand name (Aldactazide, Hydrochlorothiazide, Spironolactone). Reports on generic versions are filed under their own applications.
Reports
777
Serious
421
54% of reports
Hospitalization
271
Death reported
46
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea99
- fatigue75
- headache73
- nausea72
- diarrhoea70
- dizziness55
- cough51
- pain45
- infusion site pain41
- off label use40
- malaise37
- pneumonia36
- oedema peripheral35
- pain in extremity35
- fall34
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 11 |
| 2012 | 23 |
| 2013 | 7 |
| 2014 | 13 |
| 2015 | 25 |
| 2016 | 17 |
| 2017 | 14 |
| 2018 | 35 |
| 2019 | 28 |
| 2020 | 49 |
| 2021 | 41 |
| 2022 | 45 |
| 2023 | 90 |
| 2024 | 150 |
| 2025 | 144 |
| 2026 | 76 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,382 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion site painSignal | 41 | 86.4 | 64.1 | 3,367 |
| oedema peripheralSignal | 35 | 7.8 | 5.6 | 201 |
| coughSignal | 51 | 4.9 | 3.8 | 158 |
| dyspnoeaSignal | 99 | 4.7 | 3.9 | 296 |
| pain in extremitySignal | 35 | 3.2 | 2.3 | 52 |
| headacheSignal | 73 | 3.2 | 2.5 | 108 |
| pneumoniaSignal | 36 | 3.0 | 2.2 | 47 |
| dizzinessSignal | 55 | 3.0 | 2.3 | 72 |
| diarrhoeaSignal | 70 | 2.9 | 2.3 | 90 |
| fallSignal | 34 | 2.8 | 2.0 | 37 |
| fatigueSignal | 75 | 2.6 | 2.1 | 76 |
| nauseaSignal | 72 | 2.5 | 2.0 | 63 |
| malaiseSignal | 37 | 2.3 | 1.7 | 26 |
| pain | 45 | 2.0 | 1.5 | 22 |
| off label use | 40 | 1.2 | 0.9 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.